N-Acetyl Cysteine In Schizophrenia Resistant to Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1098442

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $981,789.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Psychiatry (incl. Psychotherapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

amino acids | clozapine | randomised controlled trial (RCT) | schizophrenia | treatment-resistant

Related Links